HELZ2

Across TCGA pan-cancer cohorts, HELZ2 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated HELZ2 data layer compared with 25 for mass-spec protein and 8 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher HELZ2 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated HELZ2 expression acts as an unfavorable survival marker, although some lineages such as HNSC show a favorable association.

PDAC, CCRCC, and HNSC are the cancer types where HELZ2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Tertile	All	0.354	0.706	.001	32	view →
CCRCC	OS	Median	All	0.903	1.000	.027	14	view →
HNSC	OS	Median	All	0.781	0.628	.023	10	view →
COAD	DFS	Median	III,IV	0.881	1.000	.038	6	view →
LSCC	OS	Median	II,III,IV	0.649	0.891	.013	4	view →
LUAD	DFS	Median	All	0.484	0.894	.010	4	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

HELZ2–PDAC (OS)

Open the PDAC breakdown →